Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Journal for Immunotherapy of Cancer
|
April 20, 2024
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2024
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2023
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)
Yuanyuan Zhao, Yuxiang Ma, Yun Fan, et al.
Cell Reports. Medicine
|
October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
Sophia Frentzas, Hui K Gan, Rasha Cosman, et al.
Frontiers in Immunology
|
November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
Qian Qiao, Chun Han, Sisi Ye, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
Lei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Cancer Immunology, Immunotherapy : CII
|
February 15, 2022
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers
Yulong Zheng, Anna Rachelle Austria Mislang, Jermaine Coward, et al.
Eclinicalmedicine
|
August 18, 2023
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Yuanyuan Zhao, Gang Chen, Jianhua Chen, et al.
Nature Medicine
|
May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Xiangyu Gao, Ke Ji, Yongning Jia, et al.
Oral Oncology
|
February 22, 2024
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
Qiu-Yan Chen, Shan-Shan Guo, Ying Luo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Journal for Immunotherapy of Cancer
|
April 20, 2024
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2024
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 7, 2023
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study)
Yuanyuan Zhao, Yuxiang Ma, Yun Fan, et al.
Cell Reports. Medicine
|
October 18, 2023
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors
Sophia Frentzas, Hui K Gan, Rasha Cosman, et al.
Frontiers in Immunology
|
November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
Qian Qiao, Chun Han, Sisi Ye, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
Lei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Cancer Immunology, Immunotherapy : CII
|
February 15, 2022
Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers
Yulong Zheng, Anna Rachelle Austria Mislang, Jermaine Coward, et al.
Eclinicalmedicine
|
August 18, 2023
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Yuanyuan Zhao, Gang Chen, Jianhua Chen, et al.
Nature Medicine
|
May 22, 2024
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial
Xiangyu Gao, Ke Ji, Yongning Jia, et al.
Oral Oncology
|
February 22, 2024
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
Qiu-Yan Chen, Shan-Shan Guo, Ying Luo, et al.
Page
of 3